Previous 10 | Next 10 |
Recently, Voyager Therapeutics ( VYGR ) announced that it had generated a partnership with AbbVie ( ABBV ) for Parkinson's disease and other neurodegenerative diseases. This deal is expected to be worth up to >$1 billion. I believe that Voyager will greatly benefit from having such a st...
Voyager Therapeutics (NASDAQ: VYGR ): Q4 GAAP EPS of -$0.70 beats by $0.02 . More news on: Voyager Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
Initiated RESTORE-1 Phase 2 trial for VY-AADC for Parkinson’s disease Began IND-enabling preclinical studies for ALS-SOD1 and Huntington’s disease programs Recently announced strategic collaborations with funding for certain programs and significant upfront and pote...
Spark Therapeutics ONCE +121% on being acquired by Roche Holding. More news on: Phoenix New Media Limited, China Internet Nationwide Financial Services Inc., uniQure N.V., Stocks on the move, Read more ...
Certain gene therapy stocks are up premarket in reaction to Roche's $4.8B bid for Spark Therapeutics. More news on: bluebird bio, Inc., Solid Biosciences, Inc., CRISPR Therapeutics, Healthcare stocks news, Stocks on the move, , Read more ...
CORAL GABLES, FL/ ACCESSWIRE / February 22, 2019 / With the new year only a few months old, the biotech stock market is already whirring with the excitement surrounding companies developing nuanced approaches to creating a wide array of new forms of treatment options for patients in need o...
Gainers: Achieve Life Sciences (NASDAQ: ACHV ) +78% . The Trade Desk (NASDAQ: TTD ) +31% . Wayfair (NYSE: W ) +29% . DMC Global (NASDAQ: BOOM ) +29% . Voyager Therapeutics (NASDAQ: VYGR ) +24% . Roku (NASDAQ: ROKU ) +23% . Universal Display (NASDAQ: OLED ) +23% . Zillow Group, Inc....
Achieve Life Sciences (NASDAQ: ACHV ) +66% on positive cytisinicline data . More news on: Achieve Life Sciences, Inc., Extraction Oil & Gas, Voyager Therapeutics, Stocks on the move, Read more ...
Voyager Therapeutics (NASDAQ: VYGR ) is up 16% premarket on light volume in response to its collaboration and option agreement with AbbVie (NYSE: ABBV ) aimed and developing and commercializing vectorized alpha-synuclein-targeting antibodies for the treatment of Parkinson's dis...
Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase 1 option payments as well as potential development, regulatory, and commercial milesto...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...